The GOG Foundation, Inc. (GOG) works with biopharmaceutical drug developers researching therapies in gynecologic cancer indications and features a network of more than 300 investigational institutions in Japan, Korea, Australia, and the US.
As part of the agreement, GOG will recommend SynteractHCR as its preferred CRO to assist its clients with their clinical trial needs.
Conversely, SynteractHCR will recommend GOG to its current and potential customers – providing sponsors access to the non-profit’s network in order to accelerate investigator selection and patient recruitment.
Wendel Barr, CEO of SynteractHCR told us the agreement with GOG combines the companies experience in drug development in oncology and gynecology.
“In aligning with GOG, we are collaborating with an organization with the same dedicated focus to bringing treatments forward in areas of greatest need, and doing so in a more targeted, precise and efficient fashion to benefit our sponsors,” Barr added.